Data-driven therapeutics company Octant Bio is exploring new frontiers of drug development with $80 million in-pocket and a freshly signed Big Pharma partnership. Octant—a historical instrument used ...
Octant Bio set out on a journey to show that the convergence of synthetic biology, chemistry, and computational techniques could lead to new drugs for patients. That destination is still distant, but ...
EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today announced it has entered into an agreement with Octant for the sale of a modular automation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback